SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS
The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors their production and use, especially for the treatment and/or prophylaxis of hormone-related diseases.
-
Page/Page column 51-52
(2012/03/26)
Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases
Estradiol (E2), the most important estrogen in humans, is involved in the initiation and progression of estrogen-dependent diseases such as breast cancer and endometriosis. Its local production in the target cell is regulated by 17β-hydroxysteroid dehydro
Oster, Alexander,Hinsberger, Stefan,Werth, Ruth,Marchais-Oberwinkler, Sandrine,Frotscher, Martin,Hartmann, Rolf W.
supporting information; experimental part
p. 8176 - 8186
(2011/02/23)
More Articles about upstream products of 1255940-11-4